Systematic Review and Meta-Analysis of Ivermectin for Treatment of COVID-19: Evidence Beyond the Hype

Marcolino, Milena Soriano; Meira, Karina Cardoso; Chagas, Victor Schulthais; Guimarães, Nathália Sernizon; Motta, Paula Perdigão; Kelles, Silvana Márcia Bruschi; Sá, Laura Caetano de; Valácio, Reginaldo Aparecido; Ziegelmann, Patrícia Klarmann

doi:10.2139/ssrn.4009120

Cited by 1 publication

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a phase 3, double-blind, randomized, placebo-controlled trial indicated that none of the Ivermectin, Fluvoxamine, and Metformin drugs prevented hypoxemia occurrence, hospitalization, and death related to COVID-19 [58]. In addition, a meta-analysis done on 25 randomized controlled trials in 2022 indicated that Ivermectin doesn't decrease the risk of mortality risk and the risk of mechanical ventilation requirements [59].…”

Section: Ivermectinmentioning

confidence: 99%

An overview on the treatments and prevention against COVID-19

Panahi¹,

Gorabi

Talaei

et al. 2023

Virol J

View full text Add to dashboard Cite

Background The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and death in others. Although humans are currently being vaccinated with several COVID-19 candidate vaccines in many countries, however, the world still is relying on hygiene measures, social distancing, and approved drugs. Result There are many potential therapeutic agents to pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme 2 (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, and herbal agents. By an understanding of the SARS-CoV-2 structure and its infection mechanisms, several vaccine candidates are under development and some are currently in various phases of clinical trials. Conclusion This review describes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents in the treatment of COVID-19 patients. In addition to reviewing the vaccine candidates that entered phases 4, 3, and 2/3 clinical trials, this review also discusses the various platforms that are used to develop the vaccine COVID-19.

show abstract

Section: Ivermectinmentioning

confidence: 99%